AEs and ADRs in italics represent events reported in the ≥2000 mg dose group at twice the rate of that in the low-dose group. aRefers to the reemergence of Parkinson’s disease symptoms, often due to a problem with drug delivery. bADRs were AEs deemed by the investigator to have at least a reasonable possibility of a causal relationship to the treatment drug/device. cExcluding those associated with the procedure/device. ADR: adverse drug reaction; AE: adverse event; SAE: serious adverse event.